Trial Information

Summary: Metastatic Colorectal Cancer Study CRAD001C2242

Novartis Oncology is conducting this clinical research study is to determine the safety and effectiveness of an investigational drug in treating participants between the ages of 18 through 65 who have metastatic colorectal cancer. Participants will be assigned to one of three groups, each receiving a different dose of the investigation drug. In addition, every participant will receive infusions of cetuximab and irinotecan. Both cetuximab and irinotecan have been approved for treatment of metastatic colorectal cancer. An "investigational drug" is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).

Participants will be asked to take 6 to 14 tablets of the study medication once a week. Participants will also receive infusions once a week.

For more information about this clinical trial, visit www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 27, 2008 at 1:00:29 PM